Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.39 |
| ▸ | MAP3K12 | Q12852 | 4/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | KHK | P50053 | 2/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3879879 | 1.00 | MALT1 (0.39) | MALT1MAP3K12TRPV1PDPK1TGFBR1 | |
| SCHEMBL3877920 | 1.00 | MALT1 (0.39) | MALT1MAP3K12TRPV1PDPK1TGFBR1 | |
| SCHEMBL5517187 | 1.00 | MALT1 (0.39) | MALT1MAP3K12TRPV1PDPK1TGFBR1 | |
| SCHEMBL3882168 | 1.00 | MALT1 (0.39) | MALT1MAP3K12TRPV1PDPK1TGFBR1 | |
| SCHEMBL13761553 | 1.00 | MALT1 (0.39) | MALT1MAP3K12TRPV1PDPK1TGFBR1 | |
| SCHEMBL3888066 | 1.00 | MALT1 (0.39) | MALT1MAP3K12TRPV1PDPK1TGFBR1 | |
| SCHEMBL13761568 | 1.00 | MALT1 (0.39) | MALT1MAP3K12TRPV1PDPK1TGFBR1 | |
| SCHEMBL13761550 | 1.00 | MALT1 (0.39) | MALT1MAP3K12TRPV1PDPK1TGFBR1 | |
| SCHEMBL3877691 | 1.00 | MALT1 (0.39) | MALT1MAP3K12TRPV1PDPK1TGFBR1 | |
| SCHEMBL3888291 | 0.94 | MAP3K12 (0.38) | MALT1MAP3K12TRPV1PDPK1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | MALT1 1393/4885MAP3K12 2603/4885TRPV1 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.